Wire · operational-macro
FDA Clears Prescription Digital Therapeutic for Negative Symptoms of Schizophrenia
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
The FDA has cleared Motivista, the first prescription digital therapeutic designed to treat negative symptoms of schizophrenia as an adjunct to antipsychotic therapy in adults. The clearance is supported by phase 3 trial data showing significant improvement in negative symptoms and good treatment adherence via a smartphone app.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 5 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
You can now prescribe a digital therapeutic for schizophrenia’s negative symptoms, opening a new treatment channel beyond drugs. Start engaging mental health clinicians to integrate this app-based therapy as part of patient care.
◆ Coverage
2 sources · first reported 5 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics